US 12,378,321 B2
ADAM17 binding molecules and uses thereof
Dimitar Nikolov, New York, NY (US); Nayanendu Saha, New York, NY (US); Zhongyu Zhu, Frederick, MD (US); Dimiter Stanchev Dimitrov, Frederick, MD (US); Dorothea Robev, New York, NY (US); and Thomas Edgeworth White, Norwalk, CT (US)
Appl. No. 17/437,065
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US); The U.S.A, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and Tri-Institutional Therapeutics Discovery Institute, Inc., New York, NY (US)
PCT Filed Mar. 7, 2020, PCT No. PCT/US2020/021603
§ 371(c)(1), (2) Date Sep. 8, 2021,
PCT Pub. No. WO2020/185635, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/815,471, filed on Mar. 8, 2019.
Prior Publication US 2023/0159653 A1, May 25, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01)] 20 Claims
 
1. An isolated ADAM17 binding molecule comprising one of:
(a) (i) a heavy chain variable region comprising: a CDR H1 domain comprising SEQ ID NO. 17, a CDR H2 domain comprising SEQ ID NO. 18, and a CDR H3 domain comprising SEQ ID NO. 19, and
(ii) a light chain variable region comprising: a CDR L1 domain comprising SEQ ID NO. 20, a CDR L2 domain comprising SEQ ID NO. 21, a CDR L3 domain comprising SEQ ID NO. 22; or
(b) (i) a heavy chain variable region comprising: a CDR H1 domain comprising SEQ ID NO. 23, a CDR H2 domain comprising SEQ ID NO. 24, and a CDR H3 domain comprising SEQ ID NO. 25, and
(ii) a light chain variable region comprising: a CDR LI domain comprising SEQ ID NO. 26, a CDR L2 domain comprising SEQ ID NO. 27, a CDR L3 domain comprising SEQ ID NO. 28; or
(c) (i) a heavy chain variable region comprising: a CDR H1 domain comprising SEQ ID NO. 29, a CDR H2 domain comprising SEQ ID NO. 30, and a CDR H3 domain comprising SEQ ID NO. 31, and
(ii) a light chain variable region comprising: a CDR LI domain comprising SEQ ID NO. 32, a CDR L2 domain comprising SEQ ID NO. 33, a CDR L3 domain comprising SEQ ID NO. 34; or
(d) (i) a heavy chain variable region comprising: a CDR H1 domain comprising SEQ ID NO. 41, a CDR H2 domain comprising SEQ ID NO. 42, and a CDR H3 domain comprising SEQ ID NO. 43, and
(ii) a light chain variable region comprising: a CDR LI domain comprising SEQ ID NO. 44, a CDR L2 domain comprising SEQ ID NO. 45, a CDR L3 domain comprising SEQ ID NO. 46; or
(e) (i) a heavy chain variable region comprising: a CDR H1 domain comprising SEQ ID NO. 47, a CDR H2 domain comprising SEQ ID NO. 48, and a CDR H3 domain comprising SEQ ID NO. 49, and
(ii) a light chain variable region comprising: a CDR LI domain comprising SEQ ID NO. 50, a CDR L2 domain comprising SEQ ID NO. 51, a CDR L3 domain comprising SEQ ID NO. 52.